A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.
News Medical on MSN
Study reveals previously unknown role for viral protein integrase in HIV's life cycle
The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.
A new study offers the first atomic-scale view of an interaction between the HIV capsid - the protein coat that shepherds HIV into the nucleus of human cells - and a host protein known as cyclophilin ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
Researchers revealed that HIV integrase forms structural filaments within the viral capsid, enabling viral infectivity. The ...
Separating full and empty adeno-associated virus (AAV) capsids during the manufacture of single-gene therapies remains a significant challenge. Ultracentrifugation and anion exchange chromatography ...
New research from the University of Minnesota School of Dentistry and Masonic Cancer Center is providing important new insights into the structure of ...
A significant advancement in molecular engineering has produced a large, hollow spherical shell nanostructure through the self-assembly of peptides and metal ions, report researchers from Japan. This ...
High-quality HIV antigens for cutting-edge solutions. On February 18, 2025, Gilead Sciences (CA, US) announced a significant milestone: the US FDA accepted their New Drug Applications (NDAs) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results